Close Menu

financial results

The firm said that TB screening market growth was impacted by a slowdown in test utilization due to the White House's immigration policies.

Luminex said that its total sample-to-answer molecular product revenue of $11.9 million grew 55 percent from $7.7 million in the third quarter of 2016.

The company, which beat analyst estimates on both the top and bottom lines, said Cologuard test volume in Q3 2017 rose 136 percent year over year.

Women's health, drug monitoring,and the company's 23andMe collaboration led organic growth in diagnostics.

Clinical testing revenues inched up less than 1 percent, while pharma services revenues rose 38 percent, the company said. 

The firm reported organic revenue growth of 5 percent and a particularly strong quarter for its analytical instruments sales.

As the company continues to push back against the recently proposed PAMA rates, it said that its acquisition strategy will offset any impact from the new rates.


The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year. 

For the third quarter of 2017, Roche Diagnostics reported that its revenues rose 6 percent to CHF 2.98 billion from CHF 2.80 billion in the prior-year quarter.

Overall, the company reported its total revenues grew 29 percent year over year to $6.83 billion. It also said that it is reorganizing the Alere business, completed earlier this month.